Antisense remains on track to positive clinical trial results
The recent completion of the monitoring phase of Antisense Therapeutics Limited's (ASX:ANP) ATL1102 Phase II Duchenne Muscular Dystrophy (DMD) trial remains on track for the end of March 2020.
As the trial is essentially completed, with all participants dosed, ANP has not been affected by COVID-19 factors and have not been adversely impacted.
Completion relates specifically to the clinical trial database for final analysis, with study results to be reported in April.
Antisense Therapeutics is developing and commercialising antisense pharmaceuticals for large unmet markets. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation.
Antisense has been conducting an open label six-month dosing trial of ATL1102 in nine non-ambulant patients with DMD at the neuromuscular centre of the Royal Children's Hospital in Melbourne.
In December 2019, ANP reported positive clinical trial results affirming ATL1102’s excellent safety profile and positive effects on disease progression endpoints.
New trial data relating to the drug’s effects (efficacy) on additional disease progression endpoints are expected once final data analysis is completed in the coming weeks.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.